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Objectives. This study attempted to evaluate whether neurohu-
moral activation at the time of hospital discharge in postinthreflon
patients helps to predict long-term prognosis and whether long-term
therapy with the angicitensin-converting enzyme inhibitor captopril
modifies this relation .
Background. Neurohomoral activation persists at the time of
hospital discharge in a large number of postinfarctiou patients. The
Survival and Ventricular Enlargement (SAVE) study demonstrated
that the anglotensin-converting enzyme inhibitor captopril improves
survival and decreases the development of severe heart failure in
patients with left ventricular dysfunction (left ventricular ejection
fraction :54017) but no overt postinfarction heart failure .
Methods. In 534 patients in the SAVE study, plasma nenrohor-
mone levels were measured a mean of 12 days after infarction .
Patients were then randomized to receive captopril or placebo and
were followed up for a mean (±SD) of 38 ± 6 months (range 24 to
55) . The association between activation of plasma neurohormones at
baseline and subsequent cardiovascular mortality or the develop-
ment of heart failure was assessed with and without adjustment for
other important prognostic factors .
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	 ACUTE MYOCARDIAL INFARCTION
Results. By univariate analysis, activation of plasma renin activity
and aldosterone, norepinephrine, atrial natriuretic peptide and
arginine vasopressin levels were related to subsequent cardiovascu-
lar events, whereas epinephrine and dopamine levels were not . By
multivariate analysis, only plasma renin activity (relative risk 1,6,
95%confidence interval 10 1 1 .0 to 2.5) and atrial natriuretic peptide
(relative risk 21, 95% CI 1.3 to 3 .8) were independently predictive of
cardiovascular morta' whereas the other neurohormones were
not. Only plasma renin activity and aldosterone, atrial natriuretic
peptide and arginine vasopressin were independent predictors of the
combined end points of cardiovascular mortality, development of
severe heart failure or recurrent myocardial infarction. Except for
1-year cardiovascular mortality, the use of captopril did not signifi-
cantly modify these relations .
Conclusions. Neurohumoral activation at the time of hospital
discharge in postinfarction patients is an independent sign of
poor prognosis. This is particularly true for plasma renin activity
and atrial natriuretic peptide . Except for 1-year cardiovascular
mortality, captopril does not significantly modify these relations .
(J Am Coll Cardiol 1994;24:583-91)
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Activation of neurohumoral systems occurs during the first few
days of an acute myocardial infarction (1) . However, by
hospital discharge, activation of most systems has generally
subsided (1,2) . The exceptions are patients taking diuretic
drugs or those with left ventricular dysfunction, where a
significant proportion may have persistent activation of one
neurohumoral system or another (1,2) .
The Survival and Ventricular Enlargement (SAVE) study
(3) demonstrated that starting the angiotensin-converting en-
zyme inhibitor captopril a mean of 11 days after infarction
resulted in long-term improvement in survival and a reduction
in the risk of developing overt heart failure or of having a
recurrent myocardial infarction . These findings, combined with
the multiple studies indicating an improved survival and a
decreased reinfarction rate when beta-adrenergic blocking
0735-1097/94/$7.(X)
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agents are started around the time of hospital discharge (4),
suggest that postinfarction neurohumoral activation is delete-
rious and that its inhibition would be desirable . If so, one might
expect neurohumoral activation at the time of hospital dis-
charge to be associated with an increased risk
and that as
increase in, plasma renin
activity would be particularly useful
in
identifying
patients that would benefit from the use of
angiotensin-converting enzyme inhibitors. Alternatively, pre-
discharge neurohumoral activation could be a poor reflection
of long-term activation and, as occurs in hypertension (5),
angiotensin-converting enzyme inhibitors may be useful re-
gardless of plasma renin activity.
The questions addressed in this analysis were t) whether
predischarge neurohumoral activation provides useful long-
term prognostic information in postinfarction patients, and
2) whether captopril modifies this relation. This was accom-
plished by measuring plasma renin activity and aldosterone,
norepinephrine, epinephrine, dopamine, arginine vasopressin
and atrial natriuretic peptide levels a mean of 12 days after
infarction in 534 patients before randomization to the SAVE
study . Activation of each neurohormone was then related to
subsequent cardiovascular mortality, reinfarction or the devel-
opment of severe heart failure . Finally, we assessed the
interaction between these neurohumoral variables and the
magnitude of the reduction in cardiac events by long-term
treatment with captopril .
Methods
Patients. The 534 patients included in this study were
participants in the SAVE study (3), a randomized, multicenter
trial
that demonstrated that the angiotensin-converting en-
zyme inhibitor captopril, where started 3 to 16 days after
infarction, improved survival in patients with left ventricular
dysfunction (defined as left ventricular ejection fraction
!540%).. Exclusion criteria included contraindications to cap-
topril and concurrent medical problems, such as renal insuffi-
ciency (creatinine >2.5 mg/dl), severe valvular heart disease,
refractory hypertension, overt heart failure or heart failure
requiring vasodilator therapy, malignancy or other conditions
thought to limit survival; geographic problems; or inability to
give informed consent (3) . Patients with isehemic symptoms or
with a markedly positive exercise test were also excluded from
the study unless a cardiac catheterization and appropriate
revascularization procedures were conducted before random-
ization . Patients who agreed to participate in the neuro-
humoral component of SAVE signed an informed consent
agreeing to have extra blood samples drawn for these assays .
Ten Canadian and three American centers participated in
this substudy . Patient recruitment for this substudy began
November 1, 1988 and ended January 28,1990 . Blood samples
were obtained before randomization a mean of 12 days (range
3 to 16 days) after myocardial infarction. Thirty-eight age-
matched subjects (mean (±SD] age 57 ± 7years ; 14women, 24
men) who were not SAVE participants were used as control
subjects. Control subjects were chosen from the various par-
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ticipating centers, had no known disease and were receiving no
medication . Neurohumoral samples were obtained front these
control subjects and were handled in a manner identical to
those of the SAVE patients .
Seventy of the 534 patients participating in the substudy had
revascularization procedures (31 had coronary artery bypass
surgery, and 39 had coronary angioplasty) performed during
the interval between their myocardial infarction and neuro-
humoral testing. Because' these patients' clinical, laboratory
and neurohumoral values were similar to those of the other
substudy patients, they were analyzed with the rest of the
group.
Neurohuntorat measurements. After an overnight fast, an
indwelling venous catheter was inserted, and the patient was
permitted to rest in the supine position for 30 min . Blood was
sampled for plasma renin activity and aldosterone, norepi-
nephrine, epinephrine, dopamine, arginine vasopressin and
atria( natriuretic peptide levels, Samples were centrifuged at
4°C and then frozen at
-.gel°C
and sent monthly to the central
laboratory (Hospital du Sacrd-Coeur de Montreal) packed in
dry ice. All sample transfers between peripheral and central
laboratories took <24 h . No samples were delayed, hemolyzed
or thawed. Neurohormones were measured as previously de-
scribed (6) as soon as received to minimize the loss of atrial
natriuretic peptide activity (7) .
Patient follow-up. Surviving patients were followed up a
mean of 38 ± 7 months (range 24 to 55). An independent
mortality committee assessed and classified deaths as to whether
they resulted from cardiovascular disease . Severe congestive heart
failure was defined as heart failure requiring hospital admission
or clinical deterioration requiring the use of open-label angioten-
sin-converting enzyme inhibition . Recurrent myocardial infarc-
tion was defined as a clinical myocardial infarction by the partic-
ipating center or the mortality committee .
Statistical analyses. All statistical analyses were performed
using the Statistical Analysis System (SAS) . The data of
participants who took part in this substudy of SAVE were
collected on the standard SAVE study forms . The 38 control
patients who were not" part of SAVE had data collected
separately. The comparability of baseline characteristics in the
two treatment groups was ascertained by unpaired two-sample
t test for continuous variables and chi-square tests for categoric
variables.
Cox proportional hazard analyses were used to investigate
the relations between neurohumoral activation at the time of
entry to SAVE and subsequent end points. For all Cox propor-
tional hazard analyses, p values, relative risks and associated
confidence intervals were determined . All analyses were per-
formed using a significance level of alpha = 0.05 (two-sided). The
end points studied were total cardiovascular mortality, 1-year
cardiovascular mortality, severe heart failure, recurrent myocar-
dial infarction and, in addition, the combined end point of total
cardiovascular mortality or severe heart failure or recurrent
myocardial infarction were evaluated . These relations were ana-
lyzed by both univariate and multivariate approaches. The univa-
riate analysis consisted of a Cox proportional hazard model with
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.
3
September IY94 :583-91
only one independent variable (tine neurohormone) . Evaluation
of the relation between end points and neurohormones was first
performed using neurohumoral levels as continuous variables .
This was then repeated with dichotomized neurohormone levels
(activation or not) . Ncurohumoral activation was defined as
L-1 .96 SD above the mean levels of age-matched control subjects .
The demographic and clinical variables used in the multivaria',C
Cox proportional hazard analyses were chosen because of their
strong univariate relations with the end points . These variables
included age, gender, previous myocardial infarction, diabetes,
hypertension, left ventricular ejection fraction and the use of
thrombolytic therapy. To exp!ore how captopril modified these
relations, Cox proportional hazard models were constructed with
neurohumoral status and treatment effect and the interaction
between neurohumoral status and treatment effect as the inde-
pendent variables and the cardiovascular end points as the
dependent variables.
Results
Patient characteristics . The characteristics of patients in-
cluded in the neurohumoral substudy resembled those of
patients in the main trial (2). Also, as in the main trial (3), in
this neurohumoral cohort there were no significant differences
in clinical or demographic characteristics between patients
randomized to receive captopril or placebo (Table 1). The
average age was 60 ± 11 years, and 82% were male . The in-
cidence of previous myocardial infarction (35%), diabetes (20%)
and hypertension (30%) were relatively high . The mean maximal
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Dala presented are mean values - SD or percent of patients, Neurohnniotal activation is a value -I .96 SD above
time mean levels of age-matched control subjects. 17o = percent of patients .
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increase in creatine phosphokinase during infarction was 13 .1
times the upper limit of normal . The Killip class with the index
(SAVE) myocardial infarction was 1 in 58%,11 in 33%, 111 in 7%
and IV in 2% . Left ventricular ejection fraction 31 ± 7% was low
(SAVE required left ventricular ejection fraction {40% as an
entry criteria) . Thrombolysis was used in 32% of patients. At the
lime of ncurohumoral sampling, 37% of patients were receiving
diuretic drugs, 34% were receiving beta-blockers, 41% were
receiving nitrates, 28% were receiving digoxin, 27% were receiv-
ing calcium-channel blocking agents, and no patients were receiv-
ing angiotensin-converting enzyme inhibitors or other vasodilat-
ing agents . There was no difference in the frequency of these
variables between the placebo and captopril groups.
Compared with age-matched control subjects, higher levels
of plasma renin activity (2 .95 ± 3.7 vs. 1 .2 ± 1 .2 ng/ml per h,
p < 0 .001), aldosterone (27 ± 28 vs. 17 ± 7 ng/dl, p < 0 .001),
norepinephrine (298 ± 192 vs. 221 ± 87 pg/ml, p < 0 .001),
dopamine (28 ± 25 vs. 21 ± 7 pg/ml, p = 0.004), arginine
vasopressin (1 .8 ± 6 .8 vs. 0 .7 ± 0.3 pg/ml, p < 0.001) and atrial
natriurvic peptide (76 ± 75 vs . 21 ± 9 pg/ml, p < 0101) were
observed, but epinephrine levels (36 ± 28 vs . 31 ± 16 pg/r,11,
p = NS) were essentially the same . These higher levels were
found in patients with and without diuretic drugs (2). The
percent of study patients with activation (?I .96 SD above the
mean levels in age-matched control subjects) was greater for
atrial natiuretic peptide than for other neurohormores (Table
1). The only difference in neurohumoral values between the
placebo and captopril groups was higher plasma atria]
natri-
uretic peptide values in the captopril group (Table 1). The
Title 1
. Demographic, Clinical and Neuroliumoral Variables
All Patients Placcha) Group
P = my
Capiopril Group
0 = No
p Vabe
(placebo vs.
wom)
0
= 534)
Q (y it
We Nwalts (9)
iM e 11 Oil 1 H
82
NS
NS
8 2 81
Previous myocardial intarction 35 37 32 NS
DOW (Q 20
21 19 NS
Hyncrtalsion ( 1 i) 30 32 28 NS
W1 ventricular ejection traction ((7 ) 31 :7 31±7 31±7 NS
Thmntulysis (5) 32 29 35 NS
Plasma renin anti, (nWml per Ida) M n 3 .7
29 +
3
;
3 .0 ± 4 .0 NS
(7 MUM 21 23 19 NS
Plasma norcpincphrine (pgmi) 2",
	
192 No ± 171 10 ± 2)0 NS
1 1 anivated
23
22 23 NS
Plasma atria) natriatclic pqtidc (pg""nfl) 76 75 70 74 81 ± 77
0
.05
1 ; anwawd (m2 56
68 (1.07
plaslim arginitw vasopressill (pginl) ~ 1 .8 -0 .8 2.0 9 .4
1 .7 ± 2 .4 NS
0 .activated 27 27
27 NS
t'LL%111 :D 1-pinephriflo (pe"1111) %A MA VIA M2
MA A MA NS
Q Anhaled
8 NS
27 .0 27.7 so t N3 NA ± 53
NS
M 36 NS
I'Lisima
(pg)all) 27 .8 ± 24.5 NA ± 26.5 MA ± 22,4 NS
Q aakawd 24 26 23 NS
586
ROULEAU ET AL,
POSTINFARCTION NEUROHORMONES AND PROGNOSIS
Table 2
. Frequency of End Points of Patients in Various Subgroups
Data presented are percent of patients.
percent of patients with activation of atrial natriuretic peptide
also tended to be higher in the captopril group, although it did
not reach statistical significance (p = 0.07) .
As expected in these high risk postinfarction patients
selected for depressed left ventricular function, the incidence
of 1-year and total cardiovascular mortality was relatively high
(Table 2). This was also true for the development of severe
heart failure, recurrent myocardial infarction and the com-
bined end point of heart failure, recurrent myocardial infarc-
tion or cardiovascular mortality. Despite the similarities in
baseline characteristics between the placebo and captopril
groups, patients randomized to receive captopril had a de-
crease in all evaluated end points. In the sample of SAVE
patients included in this neurohumoral substudy, this decrease
reached statistical significance for the end points of severe
heart failure and the combined end point of severe heart
failure, recurrent myocardial infarction or cardiovascular
mortality.
of netunhumoral activation on end points. The
univariate relations between neurohumoral activation (cate-
goric values) (defined as L1 .96 SD above the mean levels in
control' subjects) and subsequent end point events are pre-
sented in Table 3 . One -year cardiovascular mortality was
associated with activation of plasma renin activity, aldosterone
and atrial natriuretic peptide . Total cardiovascular mortality
was associated with activation of all measured neurohormones,
except for plasma epinephrine and dopamine . The develop-
ment of severe heart failure was associated with activation of
all neurohormones except plasma epinephrine, and recurrent
myocardial infarction was associated with activation of argi-
nine vasopressin and aldosterone . Activation of all neurohor-
mones except for plasma epinephri and dopamine was
associated with the; combined end point of cardiovascular
mortality, severe heart failure or recurrent myocardial infarc-
tion
. The univariate relations between neurohormone levels
and the various end points were somewhat different when
continuous values of the neurohormones were correlated to
events rather than analysis according to whether neurohu-
moral activation was present or not. Specifically, arginine
vasopressin was no longer correlated with any end point
;
plasma norepinephrine levels were correlated with 1-year
cardiovascular mortality (Wald chi-square 11 .1, relative risk
1.37,95% confidence interval [CI] 1 .14 to 1.64, p < 0.001); and
JACC Vol . 24, No. 3
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plasma renin activity correlated with recurrent myocardial
infarction (Wald chi-square 3.7, relative risk 1 .12,95% Cl 1.00
to 1.25, p = 0.056) . Otherwise, the results using continuous
neurohumoral levels resembled those using discrete categoric
analyses (activation or not).
When activation (categoric values) of various neurohumoral
systems was considered along with other variables known to
modify survival (age, gender, previous myocardial infarction,
hypertension, diabetes, thrombolysis and left ventricular ejection
fraction) in multivariate analysis (Table 4), only activation of
atrial natriuretic peptide remained significantly related to 1-year
cardiovascular mortality. In addition, atrial natriuretic peptide, as
well as plasma renin activity, continued to be associated with total
cardiovascular mortality. Activation of norepinephrine, arginine
vasopressin or aldosterone was no longer associated with total
cardiovascular mortality. Activation of arginine vasopressin con-
tinued to be related to recurrent myocardial infarction, but
aldosterone did not . Nevertheless, activation of all neurohor-
mones, except for epinephrine, dopamine and perhaps aldorte-
rone continued to be independently related to the development
of severe heart failure. Plasma renin activity, atrial natriuretic
peptide, arginine vasopressin and aldosterone also continued to
be independently related to the combined end point of recurrent
myocardial infarction, severe heart failure or cardiovascular
death. When neurohumoral levels (as continuous values rather
than according to whether a neurohonmone was activated or not)
were correlated to the various end points by multivariate analyses,
fewer relations between neurohormones and end point events
were found. No relation between neurohormone levels and the
individual end points of cardiovascular mortality, recurrent myo-
cardial infarction or the development of severe heart failure could
be found. Also, only plasma norepinephrine (Wald chi-square 5 .0,
relative risk1.15,95%a102 to 1.31, p = 0.025) and aldosterone
(Wald chi-square 3.9, relative risk 1 .03,95% CI 1 .00 to 1.06, p =
0.049) were significantly associated with the combined end point
of recurrent myocardial infarction, severe heart failure or cardio-
vascular mortality. The association between the combined end
points and plasma renin activity approached significance (Wald
chi-square 3.5, relative risk 1.07,95% CI 1.00 to 1.14, p = 0.063) .
Effect of captopril . Table 5 demonstrates the relative risk
associated with activation of a specific neurohormone in
patients according to randomization to placebo or captopril .
As one would expect from Table 3, activation of most neuro-
All
Patients
(n = 534)
Placebo
(n = 263)
Captopril
(n = 271)
p Value
(placebo vs.
captopril)
Total cardiovascular mortality (%) 16.1 18.6 13 .7 NS
1-year cardiovascular mortality (%)
9
.2
11
.0
7 .4
NS
Severe heart failure (%)
16.9
22.4
11 .4 0
.001
Recurrent myocardial infarction (%) 11 .0 13.3 8 .9 NS
Cardiovascular mortality
or
severe heart failure
or
recurrent myocardial infarction (%)
30.5 36.1 25 .1 0.006
JACC Vol . 24, No. 3
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Table 3. Univariate Relation Between
Activation of Neurohormones and Specified End
Points
hormones was associated with an increased risk of subsequent
cardiovascular events whether patients were randomized to
receive placebo or captopril . However, when the effect of
captopril on the prognostic significance of neurohumoral acti-
vation was assessed by evaluating the interaction
between
neurohumoral activation, randomization to captopril
(treat-
ment effect) and cardiovascular end points, as a general rule,
randomization to captopril had little effect
. The only exception
occurred in 1-year cardiovascular mortality, where the use of
captopril eliminated the prognostic significance of both plasma
renin activity and arginine vasopressin . When the interaction
ROULFAU l/T AL
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Wald p
Rel'iti%e Risk
Not Activated*
Activated'
Chi-Square
Value, (95'/
. CI)
I-year CV mortality
Renin
33/411(7 .8)
Norepinephrine 34,414 ($ .2)
ANP
9/20.1(4 .4)
AVP 31/388 (8 .0)
Epinephrine 42/492 (8.5)
Aldosterone
22!333 (6.6)
Dopamine 3314(16 (8 .1)
Total CV mortality
Renin 561421 (13
.3)
Norepinephrine 591414 (14.3)
ANP 16/203
(7 .9)
AVP 54/388 (13
.9)
Epinephrine 76/492 (15 .5)
Aldosterone 40/333 (12 .1))
Dopamine 60/406 (14 .8)
Severe heart failure
Renin 58/421 (13 .8)
Norepinephrine 60/414 (14 .5)
ANP 19/2113
(9.4)
AVP 57/388 (14 .7)
Epinephrine 79/492 (16.1)
Aldosterone 43/333 (12 .9)
Dopamine 70/406 (17 .2)
Recurrent Ml
Renin 43/421 ((0.2)
Norepinephrine 45/414 (10.9)
ANP 26/203 (12
.8)
AVP 33/388 (8.5)
Epinephrine 52/492 (10
.6)
Aldosterone 31)/333 (9.0)
Dopamine 47/406 (11.6)
CV mortality or severe hear)
failure or recurrent MI
Renin 1131421 (26 .8)
Norepinephrine 1141414 (27
.5)
ANP 43/2113 (21 .2)
AVP 102/388 (263)
Epinephrine 146/492 (29 .7)
Aldosterone 81/333 (24
.3)
Dopaminc
122/4(16 (30.1)
I6/I13(14 .2)
4 .5
15/121) (12
.5) 2 .3
401331 (12.1)
7.9
18/146 (12
.3) 2.6
7/42 (16.7)
3.5
27/201 (13.4) 6.7
16/128 (12
.5) 2.4
0.033
1 .9 (1 .1-3
.5)
NS
1 .6 (0 .9-2 .9)
0 .005
2
.8(t.4-5 .8)
NS 1
.6(0.9-2 .9)
0.062t
2.1(1 .0-4 .8)
(1 .009
2.1(1 .2-3 .7)
NS 1 .6(0 .9-2 .9)
30/1 13 (26
.6)
12.1 < 0 .(11)1
2.2 (1,4-3 .4)
27/120 (22.5)
5 .1 0 .024 1
.7 (1 .1-2 .7)
70/331 (21 .2) 14.8 < 1) .001
29(1 .7-5 .1))
32/146 (219) 6.6
(1 .1)1(1
1 .8 (1 .1-2 .8)
10/42 (23 .8) 2.6
NS 1 .7 ((1 .9-3 .3)
46/201 (22
.9)
11 .2 < 11 .00) 2
.1 (1 .3-3 .2)
26/128(20.3) 2
.3 NS 1 .4
(0 .9-2 .3)
32
2
1113 (28 .3) 16 .9
(1.001 2.5 (1.6-3 .8)
30/120(25 .0) 8 .8
0
.
003 1.9 (1 .3-3 .0)
711331 (21 .5) 13 .5 0.002
2.6 (1 .6 .4.3)
33/146 (22 .6) 6 .7
(1.01(1 1 .8 (1 .1-1.7)
11/42 (26.2) 4 .1 (1.043
1 .9 (LO-3 .6)
47/201 (23
.4)
11 .3
< (1
.0(11 2 .0 (1 .3-3.1)
20/128 (15 .6) < I NS
0.9 (0.6-1 .5)
16/113 (14 .2) 1.9 NS 1
.5 (0.8-2 .7)
14/12(1(11.7) < I NS 1.1 (0.6-2.0)
331331 (10
.11) < i
NS 0.8 (0.5-1 .4)
26/146(17 .8) 1)1 .8 (1.001 2 .4 (1 .4-4 .0)
7/42 (1( .7) 1
.9
NS 1 .8 (0.8-3 .9)
29/2(11 (14 .4) 4 .5 0 .035 1 .7(1.(1-29)
12/128 (9.4) =1 NS 0 .8 (0.4-1 .5)
501113 (44 .3) 15 .5 < 0 .001 2 .11(1 .4-2 .7)
49/1211(40 .8) 8 .3
0 .01(4 1.6 (1
.2-2.3)
120/331 (36 .3) 12 .5 < 0.001 19 (1 .3-2.7)
61/146(41 .8) 14 .4
<(1.001 19(1 .3-2.5)
17/42 (40
.5)
3 .1 0.077* 1 .6 (1 .0-2.6)
82/201 (40.8) 16 .7
< 0
.001 1 .9 (1 .4-2.6)
41/128 (32 .0) <I
NS 1 .0 (0.7-1 .5)
*Number (%) of patients . tp values were calculated on the basis of Cox proportional hazard analysis
. The model contains the individual neurohormonc only for
each end point . Relative risk was calculated for each neurohormone when it was activated versus not activated
. *Denotes activation of neurohormone is borderline
significant (0
.05 < p < 0.10) . ANP = a trial natriurctic peptide ; AVP = arginine vasopressin
; Cl = confidence interval ; CV = cardiovascular, MI = myocardial
infarction.
between captopril, neurohormones and cardiovascular end
points was explored using continuous neurohumoral levels, the
prognostic effects of neurohormones were found to be inde-
pendent of captopril .
Discussion
This study demonstrates that activation of any one of a
number of neurohumoral systems at the time of hospital
discharge in postinfarction patients with left ventricular dys-
function provides independent prognostic information
with
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Table 4. Prognostic Value of Neurhumoral Activation for All
Patients: Multivariate Cox Proportional Hazard Analysis
$p values were calculated on the basis of Cox proportional hazard analysis .
tActivation of neurohormone is borderline significant (0 .05 e p < 0.10)
. For
each end point, the model contains the individual neurohormone and the seven
clinical variables: age, gender, previous myocardial infarction, diabetes, hyper-
tension, left ventricular ejection fraction
. Significant neurohumoral activation
was defined as values 21
.96 SD above mean levels in age-matched control
subjects
. Relative risks were calculated for each neurohormone ;vhen it was
activated versus not activated
. Abbreviations as in Table 3.
regard to the risk of subsequent cardiovascular morbidity and
mortality. Of the neurohormones assessed, plasma atrial na-
triuretic peptide and plasma renin activity were the most
useful. Although captopril attenuates neurohumoral activation
(8), and neurohumoral activation was associated with cardio-
vascular events in this study, captopril did not significantly
modify the predictive value of neurohumoral activation . The
JACC Vol . 24, No
. 3
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only possible exception occurred for 1-year cardiovascular
mortality, where the deleterious effect of activation of plasma
renin activity or arginine vasopressin was eliminated by ran-
domization to captopril .
Evaluation of the predictive value of the various neurohor-
mones was performed using two different techniques . The first
examined plasma levels as continuous values. This more
traditional approach has the advantage of considering the
actual values measured and of appreciating subtle differences
between patients . However, it has the disadvantage of consid-
ering differences within the normal range in which the majority
of our patients could be found and of being subject to variations
that result from technical aspects, such as the preparation and
transport related to the measurement of these neurohormones .
Except for plasma norepinephrine, where continuous rather than
categoric values appeared to be more predictive of cardiovascular
events, this did not appear to be ihe preferred approach. This was
particularly true when the effects of neurohormones on prognosis
were assessed considering other important clinical variables (mul-
tivariate analyses) . By multivariate analysis, considering neuro-
hormones as continuous values identified very few significant
relations between neurohormones and cardiovascular end points,
whereas evaluating neurohormones as activated or not (categoric
approach) identified multiple significant relations . Although this
categoric approach to analysis may miss graded or subtle effects of
differences in neurohumoral levels, it minimizes informationless
variability contained in continuous neurohumoral plasma levels
by identifying only patients with marked activation oa a given
neurohumoral system .
Prognostic value of various neurohormones. Plasma renin
activity provided independent prognostic information with
regard to total cardiovascular mortality, the development of
severe heart failure and the occurrence of combined cardio-
vascular end points. The prognostic value of plasma renin
activity in these postinfarction patients with left ventricular
dysfunction is consistent with studies in patients with chronic
left ventricular dysfunction and overt heart failure in whom an
increase in plasma renin activity is associated with a high risk
of subsequent events (9,10) . However, in patients with chronic
left ventricular dysfunction but no overt heart failure, because
plasma renin activity is normal unless patients are receiving
diuretic drugs the prognostic significance of plasma renin
activity is less certain (11) . These findings coupled with the
increase and prognostic significance of plasma renin activity in
the SAVE population underscore the pathophysiologic differ-
ences that exist between the SAVE and Studies of Left
Ventricular Dysfunction (SOLVD) prevention trial popula-
tions. Of all cardiovascular events, plasma renin activity was
most closely associated with the development of heart failure .
The reasons for this association are uncertain but are most
likely related to angiotensin-Il-induced sodium and water
retention, progressive ventricular dilation and left ventricular
dysfunction caused by an angiotensin-11-induced increase in
preload, afterload and protein synthesis (12,13) . The associa-
tion between plasma resin activity and recurrent myocardial
infarction was less clear, with an association being found only
Wald
Chi-Square
P
Value`
Relative Risk
(95% CI)
1-year CV mortality
Benin
<1 NS 1 .2(0 .7-2.3)
Norepinephrinc
<1 NS
1 .1(0.6-2.1)
ANP 3 .9 0.049 2.1(1.0-4 .3)
AVP
<
1 NS
1.2(0.6-2 .2)
Epinephrine
<1 NS 1 .4(0.6-3 .1)
Aldoderone
<1 NS
1.4(0 .7-25)
Dopamine
1 .0
NS 1 .4 (0 .7-2.5)
Total CV mortality
Resin
3 .8
0.051 1,6(t.0-2 .5)
Norepinephrine
< 1 NS 1 .2(0.7-1 .9)
ANP 7 .7 0.006 2.2(l .3-3.8)
AVP 1
.9 NS 1 .4(0.9-2 .2)
Epinephrine
<1 NS 1 .2(0 .6-2 .3)
Aldosteronc
2.0 NS
1 .4 (0.9-2.2)
Dopamine
< I NS 1 .3 (0 .8-2.0)
Severe heart failure
Renin
9.3 0.002 2 .0(1 .3-3.2)
Norepinephrinc
3 .9 0.049 1 .6(1.0-2 .5)
ANP
6 .8 0
.009
2
.0(1.2-3.3)
AVP
4 .0 0.046 1 .6(1 .0-2 .4)
Epinephrine 1 .1
NS
1 .4
(0 .7-2.7)
Aldosterone
3 .4 0.0651 1 .5 (1 .0-2.3)
Dopamine <1 NS 0.8(0.5-1 .4)
Recurrent MI
Renin < 1 NS 1 .3 (0.7-2.4)
Norepinephrine
<1 NS 1 .0(0 ..5-1 .8)
ANP
2 .7 NS 0.6(0.4-1 .1)
AVP
9
.0 0 .0011 2.3(1 .3-3.8)
Epinephrine
1 .1 NS 1 .5 (0 .7-3.4)
Aldosterone 2.4 NS 1 .5 (0.9-2.6)
Dopamine
< I NS 0.8 (0 .4-1
.5)
CV mortality or severe heart
failure or recurrent MI
Resin
7
.6
0.006
1 .6(1.2-2.3)
Norepinephrine
2
.8 0.0921
1 .3(1
.0-L9)
ANP 5 .0 0.026 1 .5 (1 .1-2.1)
AVP 9
.0 0.003 1 .6(1.2-2.3)
Epinephrine < 1 NS 1 .2(o .7-2.0)
Aldosterone 6.1 0.014 1.5 (1 .1-2.1)
Dopamine < 1 NS
1.0 (0.7-1 .4)
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Table 5
. Prognostic Value of Neurohumoral Activation by Treatment Group
: Multivariate Cox
Proportional Hazard Analysis*
Placebo (activated vs.
not activated) :
Relative Risk (95% Cl)
1-Year CV mortality
Renin
	
3.12 (1
.50-6.48)
Norepinephrine 1 .47 (0.65-3.33)
ANP 2
.12 (0.94-4 .80)
AVP 2.74 (1 .32-5.68)
Epinephrine 1 .58 (0 .48-5.24)
Aldosterone 1 .95 (0.94-4 .06)
Dopamine 1 .16 (0.52-2.63)
Total CV mortality
Renin 2 .54 (1 .43-4.52)
Norepinephrine
1
.13 (0.58-2.21)
ANP 2 .33 (1 .24-4 .40)
AVP 2 .01 (1 .13-3.57)
Epinephrine 1 .55 (0 .61-391)
Aldosterone 1.69 (0.96-2.96)
Dopamine 1 .07 (0.57-2.01)
Severe heart failure
Renin 2 .49 (1 .46-4 .24)
Norepinephrine 1 .68 (0.96-2.95)
ANP
2.90 (1 .59-5.28)
AVP 1 .68 (0 .98-2.88)
Epinephrine 1 .65 (0.71-3 .83)
Aldosterone 2 .31(1 .38-3.88)
Dopamine 0 .65 (0.34-1 .25)
Recurrent MI
Renin 1 .57 (0 .75-3 .27)
Norepinephrine 0 .96 (0.42-2 .19)
ANP 0 .97 (0 .50-1 .89)
AVP 2 .10 (1 .07-4.13)
Epinephrine
1 .31 (0 .40-4.29)
Aldosterone 1 .72 (0 .89-3.34)
Dopamine
0
.70 (0 .31-1
.61)
CV mortality, severe heart
failure or recurrent MI
Renin
2 .22 (1 .45-3 .40)
Norepinephrine 1 .44 (0.91-2 .27)
ANP
2 .01 (1 .30-3.12)
AVP
2 .02 (1 .33-3 .05)
Epinephrine 1 .51(0 .16-3.00)
Aldosterone
1 .84 (1 .23-2.75)
Dopamine
0.77 (0.47-1 .25)
by univariate analysis and even then only when continuous
levels rather than categoric (activation or not) values were
being used
. A lack of correlation would be consistent with
results from the Northwick Park Heart Study (14)
. Neverthe-
less, a relation between plasma renin activity and recurrent
myocardial infarction would be consistent with
results in
hypertensive patients (15), where patients with high renin
values have been found to be at higher risk of myocardial
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Interaction ;
Captopril (activated vs.
not activated) :
Wald
Relative Risk (95% CI) Chi-Square
Value
p
0.71(0.21-2 .43) 4.09
0 .043t
1 .84 (0.73-4 .60)
0.12 NS
9.51 (1 .27-71 .04)
1 .83 NS
0.66 (0
.22-1 .96) 4.53 0
.33t
3.02 (1 .01-9.04) 0.61
NS
2
.26 (0.94-5 .46) 0.06 NS
2.36 (0.96-5 .78) 1
.31 NS
1 .77 (0.87--3.59) 0
.61 NS
2.69 (1 .40-5 .16) 3.30 0.069
6
.00(1
.84-19
.55) 1 .91 NS
1 .55 (0.79-3 .06) 0
.32 NS
1 .98 (0.77-5 .08) 0.13 NS
2.59 (1 .35-4 .98) 0
.33 NS
1 .98 (1 .01-3 .88) 1 .71 NS
2.46(1 .18-5 .13) 0.01
NS
2.65(1 .30-5 .41) 0.97 NS
2.80(1 .08-7 .30) 0.01
NS
2.07(1 .02-4.24) 0.21 NS
2
.52 (0.97-6.58) 0.43 NS
1 .46 (0.71-2.98) 1 .06 NS
1 .48 (0.68-0 .322) 2.56 NS
1 .38 (0.55-3 .47) 0 .05 NS
1 .40 (0.58-3
.38) 038
NS
0.71 (0.32-1 .61) 0 .33 NS
2.91 (1 .30-6 .49) 0 .37 NS
2.44 (0.83-7.13) 0.57 NS
1 .67 (0.75-3 .72) 0.01
NS
0.94 (0 .35-2.53) 0 .20 NS
1 .61(0.94-2.75)
0
.85
NS
1 .97(1 .20-3.24) 0 .83 NS
2.01(1 .12-3.62) 0 .01 NS
1 .71(1.04-2
.79) 0 .26 NS
1.71(0.82-3.57) 0 .06 NS
1 .91(1 .19-3.07) 0 .01
NS
1
.48 (0 .88-2
.50) 3 .27 0.071
*Neurohumoral activation was defined as values >_l
.96 SD above mean levels in age-matched control subjects
.
Relative risk and p values were calculated for activation versus inactivation for each neurohormone based on Cox
proportional hazard analysis
. For each Cox proportional hazard model, the independent variables are treatment,
neurohumoral activation and the interaction between treatment effect and neurohumoral activation
. tWald chi-square
and p values were calculated for the interaction term in each model .
infarction
. The reasons for an association between
plasma
renin activity and recurrent myocardial infarction are uncer-
tain but may be related to the potent vasoconstrictor effect of
angiotensin 11 (16),
to its atherogenic (17) and thrombogenic
(18) effects and perhaps by other, still poorly understood
genetically related mechanisms
(19) .
Plasma aldosterone, whether it was considered a continu-
ous or categoric value, was not an independent predictor of any
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one cardiovascular end point alone . Nevertheless, it was asso-
ciated with the occurrence of the combined cardiovascular end
points. These findings are consistent with previous reports (IC)
demonstrating that an increase in plasma aldosterone is a sign
of poor prognosis in patients with heart failure . Potential
mechanisms proposed to explain a detrimental effect of aldo-
sterone include increased cardiac fibrosis (20), hypokalemia
and hypomagnesemia (21). To what extent the adverse effects
of aldosterone are independent of stimulation of the renin-
angiotensin systems is unknown. However, because of the
relatively poor correlation between activation of one of these
systems and the other (2), there is reason to believe that they
are at least partially independent. In this study, nearly twice as
many patients had activation of aldosterone compared with
plasma renin activity .
Plasma atrial natriuretic peptide provided independent
information with regard to early and total cardiovascular
mortality, development of severe heart failure and combined
cardiovascular end points . Our findings at hospital discharge
are consistent with the poor prognosis observed when atrial
natriuretic peptide levels are acutely elevated after infarction
(22) . These results are also consistent with those in patients
with chronic heart failure, where atrial natriuretic peptide has
been found to be a powerful predictor of subsequent mortality
(23) . The mechanisms by which elevated atrial natriuretic
peptide levels are associated with a poor prognosis are uncer-
tain because atrial natriuretic peptide promotes vasodilation
and diuresis and suppresses activation of the renin-angiotensin
system (24), effects associated with improvement rather than
deterioration of the patient. Rather, it is most probable that
elevated levels of atrial natriuretic peptide in themselves are
not harmful but that their elevation merely reflects an unfa-
vorable underlying pathophysiologic process. Finally, because
the predictive value of atrial natriuretic peptide was indepen-
dent of left ventricular ejection fraction, other mechanisms
that lead to an increase in atrial natriuretic peptide, such as
diastolic dysfunction, must be considered potentially important
postinfarction risk factors .
By univariate analyses, plasma norepinephrine was found to
be associated with all subsequent cardiovascular events except
recurrent myocardial infarction . These associations were found
variably when norepinephrine levels were examined as contin-
uous or categoric (activated or not) values . However, when
considered along with other important variables, the indepen-
dent predictive value of plasma norepinephrine was substan-
tially weakened, remaining significant for the development of
severe heart failure and combined cardiovascular end points
only. This differs from patients with chronic heart failure,
where plasma norepinephrine is a major predictor of subse-
quent mortality after adjusting for other mortality correlates
(25). The reasons for this discrepancy are uncertain but may be
related to the lower plasma norepinephrine levels in postinfarc-
tion patients compared with patients with chronic heart failure
(I) . Other possible explanations are that circulating catechol-
amine levels do not adequately reflect adrenergic tone or that
circulating levels around the time of hospital discharge do not
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faithfully reflect long-term activation in postinfaretion patients .
That plasma epinephrine levels were unrelated to cardiovas-
cular events suggests that postinfarction prognosis is unrelated
to adrenergic activation by the adrenal glands . Little has been
published with regard to plasma dopamine levels and progno-
sis ; however, it would appear from this study that it has little
prognostic value in these patients . Nevertheless, because the
use of beta-blockers has been found to be useful in these
patient populations, further work investigating the relation
between adrenergic activation and prognosis is warranted .
Arginine vasopressin emerged as a good predictor of sub-
sequent cardiovascular events . By univariate analyses, it was
associated with all cardiovascular events except 1-year cardio-
vascular mortality and, by multivariate analysis, it was predic-
tive of development of severe heart failure, recurrent myocar-
dial infarction and combined cardiovascular end points . These
findings differ front those of patients with chronic heart failure,
where arginine vasopressin has not been found to be a particularly
useful prognostic index (26). The reasons for these differences are
uncertain but may be related to the far greater activation of this
system in p ostinfarction patients compared with patients with
symptomatic heart failure. The independent predictive value of
arginine vasopressin for the occurrence of recurrent myocardial
infarction was particularly impressive . One possible explanation is
the coronary vasoconstrictor effects of vasopressin (27,28). Al-
though the plasma levels of arginine vasopressin normally asso-
ciated with vasoconstriction are greater than those observed in
the vast majority of patients in this study, it is possible that in
susceptible patients, lower levels cause coronary spasm. A second
potential contributing mechanism is the smooth muscle prolifer-
ative effects of arginine vasopressin (29) .
Effect of captopril . Except for modifying the prognostic
value of plasma renin activity and arginine vasopressin on
1-year cardiovascular mortality, captopril had little effect on
the prognostic value of neurohormone levels on any of the
measured end points. Also, because of the generally negative
findings with captopril and the large number of statistical
comparisons made, even these two relations must be taken
with care. This is surprising considering the independent
prognostic value of plasma renin activity in this study . These
results also differ from reports of chronic heart failure, where
the beneficial effects of angiotensin-converting enzyme inhib-
itors are concentrated in patients with the most neurohumoral
activation, particularly of the renin-angiotensin system (10,30) .
The reason for this discrepancy is uncertain ; however, the
possibility of low statistical power due to inadequate sample
size must be considered . Because captopril appeared to elim-
inate the relations between plasma renin activity and early
cardiovascular death, it is also possible that activation of the
renin system is particularly deleterious in the earlier (first year)
postinfarction period or that early postinfarction levels do not
faithfully reflect long-term activation of this system . Finally, it
is possible that the beneficial effects of captopril occur through
mechanisms such as inhibition of tissue angiotensin-converting
enzyme inhibitors or other angiotensin-converting enzyme
inhibitor-related effects that may not necessarily be reflected
JACC Vol . 24, No. 3
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by levels of circulating plasma renin activity . In any case, from
this study it would appear that, in this respect, postinfarction
patients resemble hypertensive patients, a situation where
plasma renin activity does not necessarily predict the hypoten-
sive response to angiotensin-converting enzyme inhibitors (5) .
Had patients with overt heart failure been included in this
study it is possible that these relations would have differed and
that neurohumoral activation would have better identified
patients most likely to benefit from captopril therapy .
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